StockData

MannKind vs Xeris Biopharma

MNKD and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MNKD and XERS compare

Xeris Biopharma is the larger company, worth 2.3 times as much as MannKind ($3.1B against $1.3B).

Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 30.5% for MannKind).

Xeris Biopharma keeps more of each dollar of sales as profit, with a net margin of −5.1% compared with −11.1% at MannKind.

Xeris Biopharma scores higher on the StockData Score (10 against 6 for MannKind), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMNKDXERS
Size and price
Market cap$1.3B$3.1B
Share price$4.07$16.80
Change, 1 year−19.6%134%
Change, 5 years−12.1%674%
Beta (5Y)1.980.27
Employees241435
StockData Score
Total score610 (better)
Valuation score1 (better)0
Growth score24 (better)
Performance score23 (better)
Health score13 (better)
Dividend score00
Valuation
P/S3.3× (better)9.1×
EV/EBITDA39.8× (better)84.2×
FCF yield−1.4%–
Fair value$1.79–
Margin of safety−127%–
Growth
Revenue growth (TTM)30.5%36.3% (better)
Revenue growth, 5Y average39.9%70.2% (better)
Net income growth (TTM)−233%–
EPS growth (TTM)−218%–
Profitability
Gross margin89.8% (better)86.6%
Operating margin2.3%10.9% (better)
Net margin−11.1%−5.1% (better)
FCF margin−4.6%–
Return on invested capital–22.1%
Financial health
Net debt / EBITDA–3.45
Interest coverage0.3×1.3× (better)
Current ratio1.72 (better)1.45
Altman Z-score−4.453.33 (better)
Piotroski F-score58 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions56.7%59.4%
Held by insiders2.5%5.2%
Insider net buying, 12 months−$2.9M (better)−$5.8M
Short interest, % of float8.4%5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.